Neurogene Inc.

Stocks

NGNE

US64135M1053

Market Closed - Nasdaq 16:00:00 2026-09-09 EDT			5-day change	1st Jan Change
37.88 ^USD	-0.66%		-1.25%	+83.88%

08-30	Certain Common Stock of Neurogene Inc. are subject to a Lock-Up Agreement Ending on 31-AUG-2026.	CI
08-30	Certain Stock Options of Neurogene Inc. are subject to a Lock-Up Agreement Ending on 31-AUG-2026.	CI

Transcript : Neurogene Inc. - Special Call

Published on 06/29/2026 at 11:41 am EDT - Modified on 06/29/2026 at 01:51 pm EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

And welcome to Neurogene's Webcast and Conference Call. Please be advised that this event is being recorded. I will now turn the call over to Lina Li,

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about Neurogene Inc.

08-30	Certain Common Stock of Neurogene Inc. are subject to a Lock-Up Agreement Ending on 31-AUG-2026.	CI
08-30	Certain Stock Options of Neurogene Inc. are subject to a Lock-Up Agreement Ending on 31-AUG-2026.	CI
08-30	Certain Restricted Stock Units of Neurogene Inc. are subject to a Lock-Up Agreement Ending on 31-AUG-2026.	CI
08-30	Certain Performance Stock Units of Neurogene Inc. are subject to a Lock-Up Agreement Ending on 31-AUG-2026.	CI
08-30	Certain Pre-Funded Warrants of Neurogene Inc. are subject to a Lock-Up Agreement Ending on 31-AUG-2026.	CI
08-11	Neurogene Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-01	Neurogene Prices $125 Million Public Offering	MT
06-30	Neurogene Launches Public Offering	MT
06-29	Neurogene Inc. - Special Call
06-29	Neurogene Says Phase 1/2 NGN-401 Data Show Progressive Improvements in Rett Syndrome	MT
06-29	Neurogene Reports Positive Long-Term Clinical Data From Phase 1/2 Trial Of NGN-401 Gene Therapy For Rett Syndrome	CI
06-08	Neurogene Completes Dosing in Embolden Registrational Trial of Ngn-401 for Rett Syndrome	CI
06-08	Neurogene Completes Enrollment in Embolden Trial of NGN-401	MT
05-12	Neurogene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-12	Neurogene Inc Highlights Data Supporting Therapeutic Rationale For ICV Delivery Method In CNS-Targeted Gene Therapy	CI

Chart Neurogene Inc.

Duration

Period

NGNE: Dynamic Chart

Company Profile

Sector

More about the company

Income Statement and Estimates

More financial data

Ratings

More Ratings

EPS Estimates

Revisions to estimates